BeneChill Finds $600K

San Diego-based BeneChill, a firm developing medical devices for treatment of cerebral ischemia, has raised $600,000 as part of $1.2M in debt funding, according to a regulatory filing by the firm this week. Source of the new funding was not announced. BeneChill has previously raised funding from Healthcap Venture Capital, Medventure Associates, NGN Capital, and the Solon Foundation, most recently $13.5M in a Series C in July of 2009. BeneChill is headed by Alan Raffensperger, who was most recently Executive Director and Franchise Head of Amgen's Global Nephrology business. More information »